New combo tackles tough lymphoma in early trial
NCT ID NCT05270057
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug, loncastuximab tesirine, combined with a standard chemotherapy regimen (DA-EPOCH-R) in 11 adults with aggressive B-cell lymphomas. The main goal is to find the safest dose and check for side effects. It is not yet known if this combination will work better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
loncastuximab tesirine combined with chemotherapy (DA-EPOCH-R)
What this could lead to
If successful, this could lead to a more effective treatment option for aggressive B-cell lymphomas, potentially improving disease control.
What could go wrong
This is a very early (Phase 1) and small trial (11 people) focused on safety, not effectiveness. The combination may cause severe side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53705, United States